<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102553</url>
  </required_header>
  <id_info>
    <org_study_id>ABX-CT-301</org_study_id>
    <nct_id>NCT04102553</nct_id>
  </id_info>
  <brief_title>F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence</brief_title>
  <official_title>Phase III Study of F-18-PSMA-1007 vs F-18-Fluorocholine PET to Compare the Detection Rate of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ABX advanced biochemical compounds GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ABX advanced biochemical compounds GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and
      F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer
      after previous definitive treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare detection rate of metastatic prostate cancer lesions of F-18-PSMA-1007 versus F-18-Fluorocholine</measure>
    <time_frame>Within 6 months after PET/CT</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>F-18-PSMA-1007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F-18-Fluorocholine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18-PSMA-1007</intervention_name>
    <description>Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.</description>
    <arm_group_label>F-18-Fluorocholine</arm_group_label>
    <arm_group_label>F-18-PSMA-1007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18-Fluorocholine</intervention_name>
    <description>Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.</description>
    <arm_group_label>F-18-Fluorocholine</arm_group_label>
    <arm_group_label>F-18-PSMA-1007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male with original diagnosis of prostate carcinoma with prior definitive therapy

          -  suspicion of recurrence (3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more
             above nadir after radiotherapy or cryotherapy and/or PSA rise by greater than 0.2
             ng/mL after prostatectomy)

          -  life expectancy of 6 months or more as judged by the investigator

          -  willing and able to undergo all study procedures

          -  informed consent in writing (dated and signed)

        Exclusion Criteria:

          -  age: less than18 years

          -  contraindications for F-18-Fluorocholine

          -  contraindications for any of the ingredients of F-18-PSMA-1007

          -  close affiliation with the investigational site; e.g. first-degree relative of the
             investigator

          -  at the time of enrolment into this study, participating in another therapeutic
             clinical trial or has completed study participation in another therapeutic clinical
             trial within 5 days of enrolment into this trial

          -  having been previously enrolled in this clinical trial

          -  mental conditions rendering the subject incapable to understand the nature, scope, and
             consequences of the trial

          -  being clinically unstable or requiring emergency treatment

          -  being considered a vulnerable person
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hoepping, Dr.</last_name>
    <phone>0049 3528 4041 60</phone>
    <email>hoepping@abx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon Bérard LUMEN</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Brabois (Vandoeuvre-les-Nancy)</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

